Abstract:BACKGROUND:Insulin resistance (IR) in obesity is associated with the occurrence of metabolic and cardiovascular diseases. Dipepidyl peptidase 4 (DPP4) plays a pivotal role during the development of IR, and was found to be a target gene of microRNA-214 (miR-214) in our study. This study sought to assess the expression and clinical value of miR-214 in obese patients with IR, and investigate its therapeutic potential in obese rats and adipocytes with IR.METHODS:Serum expression of miR-214 in obese patients with or without IR was estimated by quantitative real-time-PCR. A receiver operating characteristic curve was plotted to evaluate the diagnostic value of miR-214 in the patients. Obesity-induced IR animal and cell models were constructed, and the therapeutic ability of miR-214 was explored.RESULTS:Serum expression of miR-214 was decreased in obese patients compared with the healthy controls, and the lowest expression was observed in the cases with IR. Downregulation of miR-214 was significantly correlated with the serum DPP4 levels and HOMA-IR of the patients upon IR conditions, and was demonstrated to perform diagnostic accuracy for distinguishing obese patients with IR from those without IR. In obesity-associated IR animal and cell models, the downregulation of miR-214 was also been detected. According to the measurement of glucose and insulin tolerance and glucose uptake abilities, we found that the overexpression of miR-214 could be used to alleviate IR in the IR models, especially when collaboratively used with DPP4 inhibitor vildagliptin.CONCLUSION:All data revealed that miR-214, as a regulator of DPP4, is decreased in obese patients with IR and may serve as a diagnostic biomarker. The upregulation of miR-214 could improve IR in obese rats and adipocytes, indicating that miR-214 has the therapeutic potential for obesity and IR.

Circulating Mir-143-3p Inhibition Protects Against Insulin Resistance in Metabolic Syndrome Via Targeting of the Insulin-Like Growth Factor 2 Receptor.

CircRNF111 Protects Against Insulin Resistance and Lipid Deposition via Regulating miR-143-3p/IGF2R Axis in Metabolic Syndrome

Urinary Mirna-29A-3p Levels Are Associated with Metabolic Parameters Via Regulation of IGF1 in Patients with Metabolic Syndrome.

[Mir-494-3p Reduces Insulin Sensitivity in Diabetic Cardiomyocytes by Down-Regulation of Insulin Receptor Substrate 1].

MicroRNA-26a Regulates Insulin Sensitivity and Metabolism of Glucose and Lipids.

A New Insight into the Roles of MiRNAs in Metabolic Syndrome

Down-Regulation of the Mir-543 Alleviates Insulin Resistance Through Targeting the Sirt1

MicroRNA-29c-3p Participates in Insulin Function to Modulate Polycystic Ovary Syndrome Via Targeting Forkhead Box O 3.

CHANGES IN microRNA (miR) profile and effects of miR-320 in insulin-resistant 3T3-L1 adipocytes.

Hsa_circ_0115355 Promotes Pancreatic Β‐cell Function in Patients with Type 2 Diabetes Through the Mir‐145/sirt1 Axis

Mir-140-5p Aggravates Insulin Resistance Via Directly Targeting GYS1 and PPP1CC in Insulin-Resistant HepG2 Cells.

Effects of miR-22-3p targeted regulation of Socs3 on the hepatic insulin resistance in mice with gestational diabetes mellitus

Aberrant Expression of Mir-214 is Associated with Obesity-Induced Insulin Resistance As a Biomarker and Therapeutic

Expression level, clinical significance and target gene functions of circu-lating miR-103b in patients with pre-diabetes mellitus

Upregulation of Microrna-204 Improves Insulin Resistance of Polycystic Ovarian Syndrome Via Inhibition of HMGB1 and the Inactivation of the TLR4/NF-κB Pathway.

MicroRNA-29 Fine-tunes the Expression of Key FOXA2-Activated Lipid Metabolism Genes and Is Dysregulated in Animal Models of Insulin Resistance and Diabetes

Dysregulation of Microrna-125A Contributes to Obesity-Associated Insulin Resistance and Dysregulates Lipid Metabolism in Mice.

Gain of Metabolic Benefit with Ablation of Mir-149-3p from Subcutaneous Adipose Tissue in Diet-Induced Obese Mice

MicroRNA-15a Positively Regulates Insulin Synthesis by Inhibiting Uncoupling Protein-2 Expression

Mechanism of Astragalus polysaccharides in attenuating insulin resistance in Rats with type 2 diabetes mellitus via the regulation of liver microRNA-203a-3p

Downregulation of Mir-181A Upregulates Sirtuin-1 (SIRT1) and Improves Hepatic Insulin Sensitivity